Company: AEMD
Filing Date: 2025-08-20
Form Type: S-1
Source: 0001683168-25-006352
Chunk: 3

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-20
Form: S-1
Chunk 3
---
 Pursuant to this prospectus, we are also offering the shares of common stock issuable upon the exercise
of the warrants, pre-funded warrants and placement agent warrants offered hereby.

Each share of our common stock,
or pre-funded warrant in lieu thereof, is being sold together with a warrant to purchase one share of our common stock. Each warrant will
have an exercise price per of $ per share (representing 100% of the combined public offering price per share of common stock (or pre-funded
warrant) and accompanying warrant in this offering), will be immediately exercisable and will expire on the fifth anniversary of the original
issuance date. The shares of our common stock and warrants are immediately separable and will be issued separately, but will be purchased
together in this Company Offering. The pre-funded warrants and warrants are not listed on any trading market and we do not intend to apply
for listing of these pre-funded warrants and warrants. Without an active market, the liquidity of these warrants will be limited.

This Company Offering will
terminate on within one year of the effective date, unless we decide to terminate (which we may do at any time in our discretion) prior
to that date. We will have one closing for all the securities purchased in this Company Offering by us. The combined public offering price
per share (or pre-funded warrant) and warrant will be fixed for the duration of this Company Offering.

We have engaged Maxim Group LLC,
or the placement agent, to act as our exclusive placement agent in connection with the securities offered by the Company in the Company
Offering. The placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered in the Company
Offering in this prospectus. Other than the placement agent warrants issued as compensation, the placement agent is not purchasing or
selling any of the securities we are offering, and the placement agent is not required to arrange the purchase or sale of any specific
number of securities or dollar amount.

In addition, this prospectus also
relates to the resale from time to time, by the selling securityholders (the “Inducement Offering”) identified in this prospectus
under the caption “Selling Securityholders” of up to 1,550,000 shares of our common stock which are issuable
upon the exercise of outstanding inducement warrants (the “Inducement Warrants”). We previously issued Inducement Warrants
to the Selling Securityholder in a private placement, pursuant to a